Press Release

{(Fomerly knowi MEDIA RELEASE Q2 FY27 standalone revenue grew 652% YoY to %44.20 crore; net profit rose to 16.01 crore Ahmedabad, 4 November 2026: Shukra Medtech Limited (formerly Shukra Pharmaceuticals Limited) (NSE: SHUKRAPHAR; BSE: 524632), a listed Indian healthcare company with businesses spanning pharmaceutical formulations, medical technology and analytical testing, today announced its unaudited standalone financial results for the quarter and six months ended 30 September 2026. Q2 FY27 financial highlights On a standalone basis, revenue from operations stood at X44.20 crore, compared with %5.88 crore in Q2 FY26. EBITDA was %22.01 crore, with a margin of 49.8%, against negative EBITDA of X0.42 crore a year earlier. Profit before tax stood at X21.13 crore, compared with X0.20 crore in Q2 FY26, while net profit rose to %16.01 crore from %2.38 crore. In the standalone segment disclosure, MedTech reported segment income of X12.51 crore, while the pharmaceutical business reported 232.27 crore. Particulars Q2 FY27 Q2 FY26 YoY change Revenue from operations 44.20 cr %5.88 cr 652% EBITDA X22.01cr %(0.42) cr Turned positive EBITDA margin 49.8% (7.1)% 5,695 bps Profit before tax R21.13cr 0.20 cr 10,549% Net profit / PAT X16.01 cr X2.38 cr 573% PAT margin 36.2% 40.5% (424) bps H1 FY27 financial highlights For the first half of FY27, standalone revenue from operations was %67.73 crore, compared with X11.27 crore in H1 FY26. EBITDA rose to 43.22 crore from %0.90 crore, with an EBITDA margin of 63.8%. Profit before tax stood at %41.37 crore, compared with X1.57 crore, and net profit rose to X31.04 crore from %3.41 crore. Particulars H1FY27 H1FY26 YoY change Revenue from operations %67.73 cr X11.27 cr 501% EBITDA R43.22 cr %0.90 cr 4,709% EBITDA margin 63.8% 8.0% 5,584 bps Profit before tax 4137 cr X1.57 cr 2,532% Net profit / PAT 231.04 cr 3.41cr 811% PAT margin 45.8% 30.2% 1,559 bps CIN : 1L24231GJ1993PLC019079 Regd. Office : 3rd Floor, “ DEV HOUSE” Opp. WIAA Office, Judges Bunglow Road, Bodakdev, Ahmedabad - 380 054. Factory Add. : 795, Rakanpur, Sola-Santej Road, Ta. Kalol, Dist. Gandhinagar - 382721, Gujarat, lndia_, Ph. : 02764-286317 Email: info@shukrapharmaceuticals.com | Website: www.shukrapharamaceuticals.com Management commentary Mr. Dakshesh Shah, Chairman and Managing Director, Shukra Medtech Limited, said: “For most of its thirty-three years, Shukra was a domestic formulations company of modest size. The standalone numbers we are reporting today — revenue of %44.20 crore for the quarter and X67.73 crore for the half year, with net profit of X16.01 crore and X31.04 crore, respectively — describe a different company. This quarter sets the foundation for that evolution. In terms of financials - what has changed is exports. This year, overseas customers account for the bulk of our growth, and serving them has meant higher inventory, longer receivable cycles and a sharper discipline on quality than the domestic trade ever demanded of us. We take that trade-off willingly. Itis a comparatively new business for us, and our first task is to make it a repeatable one rather than a good half year. Alongside this, our priority is to grow the MedTech arm. It will take a few quarters to scale, but it matters most for our long-term growth. Our years in pharmaceuticals have shown us where the gaps in healthcare are and the opportunities beyond our traditional business. We will keep strengthening the pharma operations while we build that platform.” About Shukra Medtech Limited Established in 1993 and headquartered in Ahmedabad, Shukra Medtech Limited (formerly Shukra Pharmaceuticals Limited) operates across pharmaceutical formulations, medical consumables, MedTech and analytical testing. Its manufacturing operations are based in Gujarat, with customers in India and overseas. The Company is listed on NSE (SHUKRAPHAR) and BSE (524632). Safe harbour This release may contain forward-looking statements regarding strategy, expansion and future performance. Actual outcomes may differ because of changes in market conditions, regulation, demand, costs or execution. The Company undertakes no obligation to update forward-looking statements except as required by law. For further information INVESTOR RELATIONS Shukra Medtech Limited Tuvis Consultants Shivkant Dhakad Sandhya Dubey | Founding Partner Company Secretary & Compliance Officer Email: sandhya@tuvisconsultants.com corporate@shukrapharmaceuticals.com = glaq fuvis trength and Intelligence. CIN : 124231GJ1993PLC019079 Regd. Office : 3rd Floor, “ DEV HOUSE” Opp. WIAA Office, Judges Bunglow Road, Bodakdev, Anmedabad - 380 054. Factory Add. : 795, Rakanpur, Sola-Santej Road, Ta. Kalol, Dist. Gandhinagar - 382721, Gujarat, India, Ph. : 02764-286317 Email: info@shukrapharmaceuticals.com | Website: www.shukrapharamaceuticals.com